Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On August7, 2018, Synergy Pharmaceuticals Inc. (the “Company”) issued a press release announcing financial results for the three months ended June30, 2018 and other matters described in the press release. A copy of the Company’s press release is furnished as Exhibit99.1 to this Current Report on Form8-K.
The information disclosed under this Item 2.02, including Exhibit99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
Item 2.02 Other Events.
On August7, 2018, the Company issued a press release announcing that it has entered into a licensing agreement with Luoxin Pharmaceutical Group Co.,Ltd., Shandong (“Luoxin”) providing Luoxin with exclusive rights to develop and commercialize the Company’s lead product TRULANCE®(plecanatide) for the treatment of adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in mainland China, Hong Kong and Macau The press release is attached as Exhibit99.2 to this report on Form8-K and is incorporated herein by reference
On August 7, 2018, the Company issued a press release announcing that leading U.S. pharmacy benefit manager, Express Scripts, will add TRULANCE to its National Preferred Formulary List, effective January 1, 2019. The press release is attached as Exhibit 99.3 to this report on Form 8-K and is incorporated herein by reference.
Item 2.02. Financial Statements and Exhibits.
(d) Exhibits.
SYNERGY PHARMACEUTICALS, INC. ExhibitEX-99.1 2 a18-18407_1ex99d1.htm EX-99.1 Exhibit 99.1 Synergy Pharmaceuticals Reports Second Quarter 2018 Financial Results and Business Update · TRULANCE® second quarter net sales up over 40% versus prior quarter · TRULANCE added to Express Scripts 2019 National Preferred Formulary List · Synergy secures ex-US licensing deal for TRULANCE in China – providing $12 million upfront payment and potential for future milestone and escalating royalty payments NEW YORK,…To view the full exhibit click here
About Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company’s uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.
